Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Prognostic Significance of Wilms' Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes

Blood (2024) 144 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2024-199066

Published: 2024

Journal Articles

Real World Data of FLT3 Mutation Testing Rates Among Indian Patients with Acute Myeloid Leukemia: An AI-Enabled Intervention to Improve Guideline-Compliant Care

Lingaraj Nayak, Anant Gokarn, Prasanth Ganesan, Hari Menon, Nidhi Tandon, Naresh Ramarajan, Vishal Vashistha

Blood (2024) 144 (Supplement 1): 7647.

https://doi.org/10.1182/blood-2024-209677

Published: 2024

Journal Articles

Making Treatment Free Remission “Feasible” in Low- and Middle- Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India

Sachin Punatar, Nishant Jindal, Anant Gokarn, Sumeet Mirgh, Akanksha Chichra, Lingaraj Nayak, Bhausaheb Bagal, Vinod Hande, Swapnil Chavan, Komal Kumbhalwar, Hari Menon, Navin Khattry

Blood (2024) 144 (Supplement 1): 3161.

https://doi.org/10.1182/blood-2024-209885

Published: 2024

Journal Articles

Myelodysplasia-Related Mutations in Adults and End-of-Induction Measurable Residual Disease Are Associated with Inferior Outcome in Patients with Acute Leukemia of Ambiguous Lineage

Blood (2024) 144 (Supplement 1): 6095.

https://doi.org/10.1182/blood-2024-202253

Published: 2024

Journal Articles

Quantitation of Leukemic Stem Cell-like Cells (LSC) Burden at Diagnosis Identifies Clinical Heterogeneity in the ELN22 Risk Stratification of Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 6088.

https://doi.org/10.1182/blood-2024-199067

Published: 2024

Journal Articles

NPM1 Mutated AML with Concurrent DNMT3A Mutation, and FLT3 -Internal Tandem Duplication Has Outcomes Similar to European Leukemianet Adverse Risk Category

Blood (2024) 144 (Supplement 1): 6087.

https://doi.org/10.1182/blood-2024-199065

Published: 2024

Journal Articles

Early Immune Reconstitution Post Allogeneic Transplant and Its Impact on Outcomes According to Type of Transplant

Saswata Saha, Disha Jain, Prashant Tembhare, Nishant Jindal, Puja Ramchandra Bhuibhar, Libin Jacob Mathew, Sumeet Mirgh, Akanksha Chichra, Lingaraj Nayak, Anant Gokarn, Sachin Punatar, Bhausaheb Bagal, Sweta Rajpal, Gaurav Chatterjee, Nikhil Patkar, Papagudi Ganesan Subramanian, Hari Menon, Navin Khattry

Blood (2024) 144 (Supplement 1): 7352.

https://doi.org/10.1182/blood-2024-211122

Published: 2024

Journal Articles

Diagnostic Value, Predictive Significance and Kinetics of Fecal Calprotectin in Suspected Acute Gut Gvhd / Gvhd Flare Post Allogeneic Stem Cell Transplant

Sachin Punatar, Lingaraj Nayak, Niket Mantri, Mukta Ramadwar, Prachi Patil, Shaesta Mehta, Aditya Kale, Sridhar Epari, Sridhar Sundaram, Koustubh Shekar, Anant Gokarn, Akanksha Chichra, Sumeet Mirgh, Nishant Jindal, Kalpashree Deval, Libin Jacob Mathew, Bhausaheb Bagal, Hari Menon, Navin Khattry

Blood (2024) 144 (Supplement 1): 4901.

https://doi.org/10.1182/blood-2024-209698

Published: 2024

Journal Articles

Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 4310.

https://doi.org/10.1182/blood-2024-199045

Published: 2024

Journal Articles

Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1

Blood (2024) 144 (Supplement 1): 4290.

https://doi.org/10.1182/blood-2024-199037

Published: 2024

Journal Articles

Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 2931.

https://doi.org/10.1182/blood-2024-199348

Published: 2024

Journal Articles

Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 852.

https://doi.org/10.1182/blood-2024-193534

Published: 2024

Journal Articles

Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 2953.

https://doi.org/10.1182/blood-2024-199036

Published: 2024

Journal Articles

Molecular Patterns of Resistance in Carbapenem Resistant Organisms Detected in Stool Surveillance Cultures in Patients Undergoing Hematopoietic Cell Transplant

Koustubh Shekar, Akanksha Chichra, Keshav Garg, Sujata Lall, Nishant Jindal, Niket Mantri, Sumeet Mirgh, Lingaraj Nayak, Anant Gokarn, Sachin Punatar, Libin Jacob Mathew, Hari Menon, Vivek Bhat, Navin Khattry

Blood (2023) 142 (Supplement 1): 4918.

https://doi.org/10.1182/blood-2023-184659

Published: 2023

Journal Articles

Comparison of Various Stem Cell Mobilization Regimens for Multiple Myeloma - a 15-Year Retrospective Institutional Analysis from India

Blood (2023) 142 (Supplement 1): 2225.

https://doi.org/10.1182/blood-2023-182563

Published: 2023

Journal Articles

Outcomes in Routine Clinical Practice with Methotrexate-Temozolomide-Rituximab Induction and Modified Etoposide-Cytarabine Consolidation in Newly Diagnosed Primary CNS Lymphoma

Blood (2023) 142 (Supplement 1): 987.

https://doi.org/10.1182/blood-2023-186742

Published: 2023

Journal Articles

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Blood (2023) 142 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2023-185507

Published: 2023

Journal Articles

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Blood (2023) 142 (Supplement 1): 6878.

https://doi.org/10.1182/blood-2023-180867

Published: 2023

Journal Articles

Withaferin-a Alleviates Acute Graft Versus Host Disease By Regulating Immune Cell Proliferation, Differentiation and Cytokine Storm Via Inhibition of JAK2-STAT3 Signalling

Vikram Gota, Saurabh Kumar Gupta, Deepshikha Dutta, Kajal Dalvi, Twinkle Khanka, Akanksha Chichra, Sachin Punatar, Anant Gokarn, Sumeet Prakash Mirgh, Nishant Jindal, Prashant R. Tembhare, Syed K Khizer Hasan, Lal Hingorani, Navin Khattry

Blood (2022) 140 (Supplement 1): 12669–12670.

https://doi.org/10.1182/blood-2022-164545

Published: 2022

Journal Articles

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Blood (2022) 140 (Supplement 1): 1135–1136.

https://doi.org/10.1182/blood-2022-165715

Published: 2022

NARROW

Prognostic Significance of Wilms' Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes

Real World Data of FLT3 Mutation Testing Rates Among Indian Patients with Acute Myeloid Leukemia: An AI-Enabled Intervention to Improve Guideline-Compliant Care

Making Treatment Free Remission “Feasible” in Low- and Middle- Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India

Myelodysplasia-Related Mutations in Adults and End-of-Induction Measurable Residual Disease Are Associated with Inferior Outcome in Patients with Acute Leukemia of Ambiguous Lineage

Quantitation of Leukemic Stem Cell-like Cells (LSC) Burden at Diagnosis Identifies Clinical Heterogeneity in the ELN22 Risk Stratification of Acute Myeloid Leukemia (AML)

NPM1 Mutated AML with Concurrent DNMT3A Mutation, and FLT3 -Internal Tandem Duplication Has Outcomes Similar to European Leukemianet Adverse Risk Category

Early Immune Reconstitution Post Allogeneic Transplant and Its Impact on Outcomes According to Type of Transplant

Diagnostic Value, Predictive Significance and Kinetics of Fecal Calprotectin in Suspected Acute Gut Gvhd / Gvhd Flare Post Allogeneic Stem Cell Transplant

Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)

Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1

Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)

Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia

Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients

Molecular Patterns of Resistance in Carbapenem Resistant Organisms Detected in Stool Surveillance Cultures in Patients Undergoing Hematopoietic Cell Transplant

Comparison of Various Stem Cell Mobilization Regimens for Multiple Myeloma - a 15-Year Retrospective Institutional Analysis from India

Outcomes in Routine Clinical Practice with Methotrexate-Temozolomide-Rituximab Induction and Modified Etoposide-Cytarabine Consolidation in Newly Diagnosed Primary CNS Lymphoma

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Withaferin-a Alleviates Acute Graft Versus Host Disease By Regulating Immune Cell Proliferation, Differentiation and Cytokine Storm Via Inhibition of JAK2-STAT3 Signalling

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only